Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (BLCO) delivers essential vision care solutions through its innovative contact lenses, surgical technologies, and ophthalmic pharmaceuticals. This news hub provides investors and industry professionals with timely updates on the company’s latest developments across all business segments.
Track official press releases, financial announcements, and strategic initiatives in one centralized location. Our curated collection includes updates on product approvals, earnings results, research breakthroughs, and partnerships that shape the future of eye health innovation.
Discover how BLCO’s three core segments – Vision Care, Surgical, and Ophthalmic Pharmaceuticals – continue advancing ocular treatment standards worldwide. The company’s commitment to clinical excellence and regulatory compliance remains central to all updates shared here.
Bookmark this page for direct access to verified information about Bausch + Lomb’s market activities. Check regularly for new developments impacting the vision care industry and BLCO’s position as a leader in medical eye solutions.
Bausch + Lomb reported first-quarter 2022 revenues of $889 million, up 1% year-over-year, with organic revenue growth of 5%. The Vision Care and Surgical segments drove performance, while the Ophthalmic Pharmaceuticals segment saw a 5% decline. GAAP net income was $20 million, down from $27 million a year prior. Adjusted EBITDA was $170 million, a decrease of $28 million. The company forecasts full-year revenues of $3.75 to $3.80 billion, reflecting anticipated growth of 4-5%.
Bausch + Lomb announced seven presentations featuring research on their new Biotrue® Hydration Plus Multi-Purpose Solution and Biotrue® Hydration Boost lubricant eye drops at the American Optometric Association's Optometry's Meeting from June 7-8, 2022. The company aims to share clinical and antimicrobial efficacy data, particularly emphasizing the use of hyaluronan, a natural tear moisturizer. Additionally, Bausch + Lomb will host various sponsored education events during the meeting in Chicago from June 15-18, 2022, targeting eye care professionals and digital gamers.
Bausch + Lomb (NYSE/TSX: BLCO) has launched a social media campaign during June, recognized as Cataract Awareness Month, to enhance public knowledge about cataracts and the necessity of routine screenings. The initiative is driven by the pressing need to address cataracts, which affect over 25 million Americans and are projected to rise by 50% by 2032. Educators aim to alleviate patient anxiety regarding cataract surgery, a procedure noted for its safety and effectiveness. The campaign encourages open discussions between patients and eye care professionals under the hashtag #CataractsDontWait.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched its new Biotrue® Hydration Plus Multi-Purpose Solution in the U.S., designed for contact lens users. This solution features 25% more hyaluronan for increased moisture, effective cleaning, and a triple disinfectant system. Approximately one-third of the 45 million U.S. contact lens wearers suffer from dryness. The product is now available at major retailers with prices starting at $7.99. Bausch + Lomb also promotes recycling through its unique eye care recycling program.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will announce its first-quarter 2022 financial results on June 8, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow to discuss the results and provide a business update. Materials will be available on the company's Investor Relations website before the call.
Founded in 1853, Bausch + Lomb focuses on eye health products, with a portfolio of over 400 products and a presence in nearly 100 countries.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has received approval from Health Canada for LUMIFY®, the first over-the-counter eye drop containing low-dose brimonidine to relieve eye redness due to minor irritations. This innovative product will be available in Canada by July 2022. Clinical trials show LUMIFY® significantly reduces ocular redness within one minute, lasting up to eight hours. It boasts a 95% satisfaction rating from a home-use study conducted with over 300 participants. This approval expands the company's portfolio in eye care products and addresses unmet needs in the market.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) reported its Q1 2022 financials, showing total revenues of $889 million, up from $881 million in Q1 2021, with an organic increase of approximately 5%. However, net income fell to $20 million from $27 million, marking a $7 million decrease. Adjusted EBITDA also declined to $170 million from $198 million, impacted by dis-synergies and higher R&D expenses. Cash flow from operations dramatically decreased to $3 million compared to $188 million in the prior year, primarily due to timing of intercompany settlements and separation-related costs.
Bausch + Lomb (NYSE/TSX: BLCO) announced that CEO Joseph C. Papa will speak at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:30 a.m. ET. A live webcast will be accessible on the company's Investor Relations page. Bausch + Lomb is a prominent global eye health company founded in 1853, focusing on a diverse portfolio of over 400 products, including contact lenses and surgical instruments, with operations in nearly 100 countries.
Bausch + Lomb Corporation and Bausch Health Companies announced the closing of Bausch + Lomb's IPO, selling 35 million shares at $18.00 each, generating $630 million. Bausch Health retains approximately 90% of Bausch + Lomb's shares. The IPO proceeds and new loans will be used to repay existing debts, including Bausch Health’s 6.125% Notes due 2025. Bausch Health also canceled the redemption of its 9.000% Senior Notes due 2025. The IPO began trading under the ticker symbol BLCO on May 6, 2022.
